- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Non-small cell lung cancer (NSCLC) is any type of epithelial lung cancer different from small-cell lung carcinoma (SCLC). NSCLC accounts for about 80-85% of all lung cancers. The most common sub-types of NSCLC are squamous cell carcinoma, large-cell carcinoma, and adenocarcinoma. These subtypes, which start from different types of lung cells, are grouped together as NSCLC because their treatment and prognoses (outlook) are often similar.
Showing the single result
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
PD-1 |
Monoclonal Antibody |
Libtayo® |
50 mg/mL |
– |
5 mg |
tba |
tba |
569,00 € |
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany